Glaxo Limiting Swine Flu Testing

(Bloomberg) -- The swine flu shot that GlaxoSmithKline Plc is developing will be tested on a limited number of people.“The total population studied in clinical trials will be limited due to the need to provide the vaccine to governments as quickly as possible,” the London-based company said in a statement today.